Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease

Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease

Iron-deficiency anemia is the most common reason for worsening of the anemia characteristically seen in chronic kidney disease (CKD). Ferric carboxymaltose (FCM) is a macromolecular hydroxide ferric carbohydrate complex that allows high-dose iron to be administered parenterally for gradual, controll...

Full description

Bibliographic Details
Main Authors: Patricia Garcia-Ortega, Ines Jimenez-Lozano, Álejandro Cruz, Aurora Fernandez Polo, Mercedes Lopez, Gema Ariceta
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pediatrics
Subjects:
pediatrics
kidney disease
intravenous iron
ferric carboxymaltose
iron deficiency
anemia
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.967233/full

Similar Items

Similar Items